# Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

> **NCT04833504** · — · COMPLETED · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 39 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Transformed Follicular Lymphoma
- Primary Mediastinal Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** CD19 CAR-T Expressing IL7 and CCL19

## Key facts

- **NCT ID:** NCT04833504
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-22
- **Primary completion:** 2023-09-22
- **Final completion:** 2024-10-01
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04833504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04833504, "Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04833504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*